Vor Biopharma Inc. Annual Report Summary

I’ve put together this guide to help you understand Vor Biopharma’s performance over the past year. My goal is to turn complex filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Vor Biopharma is a clinical-stage biotech company. Think of them as a startup building a better engine for the immune system to fight cancer and autoimmune diseases. They aren't selling products yet; they are entirely in the research and development phase. Their focus has shifted heavily toward telitacicept, a drug candidate licensed to treat autoimmune conditions like Lupus and IgA Nephropathy.

2. Financial performance: The "Cash Burn" Reality

Because Vor is still researching, they aren't generating sales revenue. For 2024, the company reported a $146.5 million loss, compared to $155.2 million in 2023. By the end of 2024, they held about $128.4 million in cash and investments. They are in "spend-to-grow" mode, relying on selling more shares to investors to keep the lights on.

A major change: In September 2025, the company performed a "1-for-20 reverse stock split." This doesn't change the company's value, but it reduces the number of shares while increasing the price per share. They did this to keep the stock price above the $1.00 minimum required to stay listed on the Nasdaq.

3. Major wins and challenges

• Wins: They bet big on telitacicept by licensing it from a Chinese company, RemeGen. This gives them a pipeline of treatments for serious diseases. They also raised $100 million in early 2025 to fund these clinical trials.
• Challenges: They have no in-house manufacturing and rely entirely on third-party contractors. If these partners fail or raise prices, Vor faces significant operational pressure. They are also entering a crowded market where giants like Amgen and Johnson & Johnson already compete. Vor must prove their drug is safer or more effective to win market share.

4. The "Telitacicept" Bet

Vor’s future is now tied to telitacicept. They paid $125 million upfront and owe up to $330 million in regulatory milestones, plus billions in potential sales bonuses.

• Patent Protection: Their core patent expires in 2028, but they have newer patents covering specific uses that could protect the business into the 2040s. This is vital to prevent generic competition after 2028.

5. Key risks

• Dilution: To pay RemeGen and fund operations, they keep issuing new shares. This reduces your ownership percentage in the company.
• Regulatory Hurdles: They rely on data from trials conducted in China. The FDA might not accept this data, which could force Vor to start expensive, multi-year U.S. trials.
• Competition: They are fighting well-funded pharmaceutical companies that have massive marketing budgets and distribution networks.

6. Future outlook

Vor is a high-risk, high-reward startup. They are betting everything on telitacicept. If the data holds up and they navigate the FDA, they have a path to market. If not, they have little to fall back on. Investors should watch their "cash runway." They expect their current cash to last only until the second half of 2026, meaning another share sale is likely coming.

---

Decision Checklist:

• Monitor the Cash Runway: Keep an eye on their quarterly cash balance; if it drops significantly, expect further dilution.
• Watch the FDA: Any news regarding the acceptance of Chinese clinical trial data is the most critical indicator for the company's timeline.
• Track Partnerships: Since they rely on third-party manufacturers, any updates on supply chain stability are vital for their long-term success.